share_log

Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Maintains $7 Price Target

Benzinga ·  Jun 27, 2024 06:32

Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $7 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment